Literature DB >> 31869258

Old world cutaneous leishmaniasis in Iran: clinical variants and treatments.

Alireza Firooz1, Hossein Mortazavi2, Ali Khamesipour1, Maryam Ghiasi2, Robabeh Abedini2, Kamran Balighi2, Nafiseh Esmaili2, Mansour Nassiri-Kashani1, S Ebrahim Eskandari1, Mehdi Mohebali3, Akram Mir Amin Mohammadi1, Yahya Dowlati1.   

Abstract

BACKGROUND: Old World cutaneous leishmaniasis (OWCL) is endemic in Iran and most cases of cutaneous leishmaniasis (CL) are caused by Leishmania major, and then Leishmania tropica, and rarely by Leishmania infantum.
OBJECTIVE: We aimed to describe clinical variants of OWCL and their treatments.
METHOD: Through literature search in PubMed, Scopus and Embase and google scholar, we have found articles about variant clinical pictures of OWCL and their treatments.
RESULTS: The following clinical variants of OWCL namely; localized forms, zosteriform, erysipeloid, eczematoid, warty, localized Leishmania lymphadenitis, sporotrichoid, hyperkeratotic, impetiginized, mucosal involvement in CL, lupoid leishmaniasis, chronic lesions due to leishmanization, disseminated cutaneous leishmaniasis, reactivation of CL after transplantation and coexistence of CL with other diseases, are reported from Iran. The mainstay of therapy remains pentavalent antimonial compounds and cryotherapy is an adjuvant to therapy. Treatment with antifungal agents, miltefosine, amphotericin B and herbal extract such as ZH-E have also been used. Treatment of CL in chronic cases and in immunosuppressed patients is difficult and relapse may occur.
CONCLUSION: In clinical variants of CL with long duration and multiple lesions, systemic pentavalent antimonial compounds are first step of therapy. In case of incomplete response or resistant to classic treatment, combination therapy is indicated.

Entities:  

Keywords:  Old World cutaneous leishmaniasis; clinical variants; pentavalent antimonial; treatment

Mesh:

Substances:

Year:  2020        PMID: 31869258     DOI: 10.1080/09546634.2019.1704214

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  9 in total

1.  The level of interleukin-17, 23, and gamma interferon in cutaneous leishmaniasis patients before and after intra lesion treatment.

Authors:  Mehdi Ghazanfari; Bahador Shahriari; Vahid Rahnama; Meisam Khazaei; Shahrbanou Naderi; Mohammad Hossein Motazedian
Journal:  J Parasit Dis       Date:  2022-02-03

2.  Cytotoxicity of Amphotericin B and AmBisome: In Silico and In Vivo Evaluation Employing the Chick Embryo Model.

Authors:  Ahmad Khosravi; Iraj Sharifi; Hadi Tavakkoli; Elaheh Molaakbari; Sina Bahraminegad; Ehsan Salarkia; Fatemeh Seyedi; Alireza Keyhani; Zohreh Salari; Fatemeh Sharifi; Mehdi Bamorovat; Ali Afgar; Shahriar Dabiri
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

3.  Leishmania tarentolae as Potential Live Vaccine Co-Expressing Distinct Salivary Gland Proteins Against Experimental Cutaneous Leishmaniasis in BALB/c Mice Model.

Authors:  Mahya Sadat Lajevardi; Elham Gholami; Tahereh Taheri; Hamzeh Sarvnaz; Sima Habibzadeh; Negar Seyed; Yousef Mortazavi; Sima Rafati
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

4.  The role of ATP-binding cassette transporter genes expression in treatment failure cutaneous leishmaniasis.

Authors:  Mohammad Javad Boozhmehrani; Gilda Eslami; Ali Khamesipour; Abbas Ali Jafari; Mahmood Vakili; Saeedeh Sadat Hosseini; Vahideh Askari
Journal:  AMB Express       Date:  2022-06-16       Impact factor: 4.126

5.  Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.

Authors:  Maryam Mahdavi; Reihaneh Aryan; Yalda Nahidi; Mehrdad Teimoorian; Vahid Mashayekhi
Journal:  Clin Case Rep       Date:  2020-11-24

6.  The effect of geo-climatic determinants on the distribution of cutaneous leishmaniasis in a recently emerging focus in eastern Iran.

Authors:  Mehdi Karamian; Mohammad Amin Ghatee; Majid Shayesteh; Walter Robert Taylor; Saeed Mohebi-Nejad; Ghasem Taheri; Mohammad Reza Jamavar
Journal:  Parasit Vectors       Date:  2021-10-15       Impact factor: 3.876

7.  Anti-leishmanial effects of resveratrol and resveratrol nanoemulsion on Leishmania major.

Authors:  Parisa Mousavi; Bahman Rahimi Esboei; Maryam Pourhajibagher; Mahdi Fakhar; Zabihollah Shahmoradi; Seyed Hossein Hejazi; Hadi Hassannia; Ayatollah Nasrollahi Omran; Hamid Hasanpour
Journal:  BMC Microbiol       Date:  2022-02-15       Impact factor: 3.605

8.  Immunogenic properties of empty pcDNA3 plasmid against zoonotic cutaneous leishmaniasis in mice.

Authors:  Hossein Montakhab-Yeganeh; Reza Shafiei; Mehdi Najm; Leila Masoori; Ashok Aspatwar; Alireza Badirzadeh
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

9.  Outbreak of cutaneous leishmaniasis before and during the COVID-19 pandemic in Jahrom, an endemic region in the southwest of Iran.

Authors:  Samaneh Mazaherifar; Kavous Solhjoo; Amir Abdoli
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.